Madrigal Accelerates Expansion of its MASH Combination Therapy Portfolio Centered Around Rezdiffra
From a Single-Product Company to a MASH Platform Company
Madrigal Pharmaceuticals (MDGL) is building a combination therapy portfolio to address all stages of MASH, based on Rezdiffra. Rezdiffra is an oral thyroid hormone receptor beta (THR-Ξ²) agonist containing resmetirom, an approved targeted therapy for non-cirrhotic F2~F3 MASH. In the first quarter of 2026, net sales increased by 127% year-on-year to USD 311.3 million, and the number of patients receiving treatment exceeded 42,250. This cash-generating power and commercial infrastructure provide a strategic foundation for continued acquisition of external assets.
Combination Design for Metabolic Improvement and Anti-Fibrotic Effects
MGL-2086, acquired from CSPC Pharmaceutical Group (1093.HK), is an oral small molecule candidate targeting the GLP-1 receptor, with Phase 1 clinical trials scheduled to begin in the second quarter of 2026. Ervogastat, acquired from Pfizer (PFE), is an oral Phase 2 asset that inhibits DGAT-2, an enzyme involved in triglyceride synthesis, and drug-drug interaction studies with Rezdiffra are scheduled to begin in the fourth quarter of 2026. The strategy aims to combine weight/metabolic control with improvements in liver fat and fibrosis, targeting a broader patient population and higher treatment response rates than Rezdiffra monotherapy. This aligns with the development rationale that combination therapy should address the multi-pathogenic nature of MASH.
Regulatory Head Start Followed by Intensified Competition
The U.S. FDA granted accelerated approval for Rezdiffra on March 14, 2024, and the European Union granted conditional marketing authorization on August 18, 2025. Both approvals are for the treatment of non-cirrhotic F2~F3 adult MASH in combination with diet and exercise, and require submission of confirmatory Phase 3 clinical trial results. Novo Nordisk's (NVO) Wegovy, a GLP-1 receptor agonist, received accelerated approval for the same U.S. indication on August 15, 2025, becoming a direct competitor. Madrigal is accelerating the development of its combination assets and Phase 3 clinical trials for F4 compensated cirrhosis, reflecting the reality that its period of being the sole leader has shortened.
Pipeline and Economic Viability of Transactions
The MGL-2086 agreement consists of an upfront payment of USD 120 million, development, regulatory, and commercial milestone payments of up to USD 2 billion, and royalties on net sales. The ervogastat agreement includes an upfront payment of USD 50 million, development and regulatory milestone payments of up to USD 70 million, a low double-digit royalty, and two early-stage MASH assets. Competitors include Novo Nordisk with its Phase 3 FGF21 analog efruxifermin, GSK with efimosfermin, and Roche with pegozafermin. Therefore, Madrigal's expansion is not simply diversification, but a capital allocation strategy to establish a treatment algorithm before competing FGF21 injectables enter the market, leveraging the oral combination convenience and Rezdiffra's prescription base.
Rezdiffra's net sales of USD 311.3 million and 42,250 patients in the first quarter of 2026 demonstrate Madrigal's commercial foundation to support the development costs of Phase 1 MGL-2086 and Phase 2 ervogastat. In the short term, with Wegovy already approved for F2~F3 MASH, prescription growth rate, insurance coverage, and combination safety studies will determine its value. In the medium to long term, expansion of the Phase 3 trial for F4 and successful combination with GLP-1 and DGAT-2 could expand Rezdiffra's patient base and duration of treatment. However, Novo Nordisk's Phase 3 efruxifermin, GSK's Phase 3 efimosfermin, and Roche's pegozafermin will intensify anti-fibrotic competition, making clinical differentiation and validation of transaction returns essential.